-
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments | Morningstar
Source: Buzz FX / 08 Nov 2024 07:31:27 America/Chicago
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Ac
Read more...